



Lymphoma Predisposing Gene in an Extended Family: CD70 Signaling Defect

Khusan Khodzhaev^{1,2} · Sema Buyukkapu Bay³ · Rejin Kebudi³ · Didem Altindirek^{1,2} · Aysenur Kaya⁴ · Yucel Erbilgin¹ · Ozden Hatirnaz Ng⁵ · Ayca Kiykim⁶ · Funda Cipe Erol⁴ · Feride Sen Zengin⁷ · Sinem Firtina⁸ · Yuk Yin Ng⁹ · Basak Adakli Aksoy¹⁰ · Muge Sayitoglu¹

Received: 18 February 2020 / Accepted: 26 June 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

Genome-wide sequencing studies in pediatric cancer cohorts indicate that about 10% of patients have germline mutations within cancer predisposition genes. Within this group, primary immune deficiencies take the priority regarding the vulnerability of the patients to infectious agents and the difficulties of cancer management. On the other hand, early recognition of these diseases may offer specific targeted therapies and hematopoietic stem cell transplantation as an option. Besides therapeutic benefits, early diagnosis will provide genetic counseling for the family members. Within this context, an extended family with multiple consanguineous marriages and affected individuals, who presented with combined immune deficiency (CID) and/or Hodgkin lymphoma phenotype, were examined by exome sequencing. A pathogenic homozygous missense *CD70* variation was detected (NM_001252.5:c332C>T) in concordance with *CD70* phenotype and familial segregation was confirmed. *CD70* variations in patients with CID and malignancy have very rarely been reported. This paper reports extended family with multiple affected members with CID and malignancy carrying a missense *CD70* variation, and reviews the rare cases reported in the literature. Primary immune deficiencies appear to be a potential cause for pediatric cancers. Better focusing on these inborn disorders to prevent or make an early diagnosis of malignant transformation and reduce mortalities is important.

Keywords *CD70* · immune deficiency · lymphoma · EBV · malignancies

Introduction

The last decade has seen an enormous increase in research on genetic susceptibility to childhood cancer, which has led to

many important insights. Germline components of cancer predisposition showed that up to 10% of children and adolescents with cancer are associated with inherited mutations. Identification of germline alterations is very important for

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s10875-020-00816-4>) contains supplementary material, which is available to authorized users.

✉ Rejin Kebudi
rejinkebudi@yahoo.com

¹ Aziz Sancar Institute of Experimental Medicine, Genetics Department, Istanbul University, Istanbul Turkey

² Institute of Health Sciences, Istanbul University, Istanbul Turkey

³ Oncology Institute, Division of Pediatric Hematology-Oncology, Istanbul University, Istanbul Turkey

⁴ Faculty of Medicine, Department of Pediatric Allergy Immunology, Istinye University, Istanbul Turkey

⁵ Department of Medical Biology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul Turkey

⁶ Faculty of Medicine, Division of Pediatric Allergy Immunology, Istanbul University Cerrahpasa, Istanbul Turkey

⁷ Intensive Care Unit, Erzurum Education and Research Hospital, Erzurum Turkey

⁸ Faculty of Art and Science, Department of Molecular Biology and Genetics, Istinye University, Istanbul Turkey

⁹ Genetics and Bioengineering Department, Istanbul Bilgi University, Istanbul Turkey

¹⁰ Department of Pediatric Hematology Oncology, Altınbaş University, Istanbul Turkey

testing the family members at risk and surveillance. A variety of genetic disorders lead to increased risk for cancer development including Down syndrome, RASopathies, chromosome breakage syndromes, and primary immune deficiencies [1].

Up to date several genes (such as *ITK* [2–4], *SH2D1A* [5], *MAGT1* [6–8], *CTPS1* [9], *CD27* [10], *CD70* [11–13], *CORO1A* [14, 15], *RASGRP1* [15–17], *TNFRSF9* [18], *STK4* [19, 20], *CARMIL2* [21–23], and *PRKCD* [24, 25]) were found to be associated with immunodeficiency and predisposition to EBV-induced lymphoma [26–29]. Recently, an autosomal recessive combined immunodeficiency (CID) phenotype associated with EBV-induced malignancy has been described as a result of rare *CD70* gene variations [11–13]. *CD70* is a member of tumor necrosis factor superfamily (TNFS) and the ligand for *CD27* [30, 31]. Co-activation of *CD27* and *CD70* regulates the survival, function, and differentiation of T, B, NK, and plasma cells [32–36]. In the CID patients and mouse models, disruption of *CD27*-*CD70* showed impaired memory responses against different viruses [37, 38]. Moreover, co-activation of *CD27*-*CD70* on B cells triggers plasma cell formation and increased IgG production [39]. *CD70* expression is not restricted to healthy activated T and B cells but also is found to be expressed in different hematological cancers including lymphomas [40], chronic lymphocytic leukemia (CLL) [41], and multiple myelomas (MM) [42]. Here, we describe a homozygous *CD70* mutation in a family with many affected individuals with immunodeficiency and malignancies.

Patients and Methods

Patients

Hereby, we present a family with multiple consanguineous marriages and individuals affected with lymphoma and/or immune deficiency (Fig. 1 and Table 1). Two siblings diagnosed with Hodgkin's lymphoma (HL) and whose parents had a consanguineous marriage were referred to our center for further evaluation and treatment.

The first sibling (V-1) was diagnosed with stage IIIsB Hodgkin lymphoma of nodular sclerosing histopathology, at 18 months of age in the local university hospital in the Northeastern part of Turkey. Treatment had been initiated with two courses of chemotherapy consisting of vincristine, etoposide, prednisone, and doxorubicin (OEPA), as per the Euronet-Pediatric Hodgkin Lymphoma-C1 protocol after which a partial remission was attained and he was referred to our center. Treatment continued with the same protocol, with four additional courses of cyclophosphamide, vincristine, procarbazine, prednisone (COPP) chemotherapy. He experienced a relapse right after the sixth course. He received three courses of chemotherapy consisting of ifosfamide, etoposide,




Fig. 1 Five generations of the pedigree with the index V-3. Indicated numbers within circles and squares are number of individuals, who were reported not having any clinical phenotypes

carboplatinum (ICE) with a complete response followed by high dose chemotherapy and autologous stem cell transplantation. He had a second relapse after 3 months, was treated with targeted therapy (antiCD30 monoclonal antibody-brentuximab) and ICE, and he achieved complete response. Treatment continued with radiotherapy. He is under follow-up for 52 months since diagnosis of HL and with no evidence of disease. Due to recurrent infections and history of consanguineous marriage in the family, the immunological evaluation revealed a severe CD4 T cell lymphopenia, which was thought to be compatible with combined immune deficiency (Table 1). Allogeneic hematopoietic stem cell transplantation has been performed when a fully matched unrelated donor was found (Table 2).

The second sibling (V-3), at 3 years of age, was diagnosed with stage IIIsB Hodgkin lymphoma of mix cellular histopathology in the local university hospital in the Northeastern part of Turkey and was referred to our center for further evaluation and treatment at the same time as her brother who had experienced a relapse of Hodgkin lymphoma (V-1). Treatment was initiated with two courses of chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine (COPP/ABV) chemotherapy, as per our institutional protocol [43], after which a partial remission was attained. Treatment continued with the same protocol, with four additional courses of COPP/ABV chemotherapy. She experienced a relapse right after the sixth course. She received three courses of chemotherapy consisting of ifosfamide, etoposide, and carboplatinum (ICE) with a complete response followed by high dose chemotherapy and

Table 1 Clinical characteristics of individuals with immunodeficiency and/or lymphoma

	V1	V2	V3	V4	IV6	IV7	IV8	IV10
Age	5 years	40 days	6 years	8 years	3 months	20 years	17 years	14 years
Age of diagnosis	1.5 years	-	3 years	6 years	-	15 years	12 years	14 years
Cancer	Hodgkin lymphoma stage IIIsB	-	Hodgkin lymphoma stage IIIsB	-	-	Hodgkin lymphoma	Hodgkin lymphoma	-
Immunodeficiency	Low T cells and hypogammaglobulinemia	?	Low T cells and hypogammaglobulinemia	Decreased CD4/CD8 ratio	-	-	-	Decreased CD4/CD8 ratio, hypogammaglobulinemia
Infections	EBV	-	EBV	EBV	-	NA	NA	HSV1 encephalitis, recurrent pneumonia, chronic lung disease
Treatments at *initial diagnosis, **at relapse, ***for CID	**2 courses of OEP/A4 courses of COPP, *(ICE brentuximab autologous HSCt radiotherapy, **allogeneic HSCt at 5 ^{0/12} years of age		*6 courses of COPP/ABV, **ICE autologous HSCt ***allogeneic HSCt at 6 years of age	***Rituximab and allogeneic HSCt at age 8				
Last status	Alive	Ex	Alive	Alive	Ex	Ex	Alive	Alive
ANS/ μ l	1950 [2300–7000/ μ l]	NA	3553 [2300–7000/ μ l]	3900 [2300–7000/ μ l]	NA	NA	7600	NA
ALS/ μ l	2960 [1000–11,000/ μ l]	NA	2550 [1000–11,000/ μ l]	3200 [1000–11,000/ μ l]	NA	NA	2000	NA
PLT $10^3/\mu$ l	195 [150–450]	NA	281 [150–450]	301 [150–450]	NA	NA	300 [150–450]	300 [150–450]
CD45	96% [90–100] #2841	NA	96% [90–100] #2448	88% [70–99] #2816	NA	NA	NA	98% [80–99]
CD3	60% [53–75]	NA	63% [53–75]	69% [57–86]	NA	NA	NA	68% [50–75]
CD4	#1776 [1400–3700]	NA	#1606 [1400–3700]	#2208 [1200–2600]	NA	NA	NA	26% [25–55]
CD8	6% [32–51]	NA	16% [32–51]	28% [29–57]	NA	NA	NA	38% [15–35]
CD19	#178 [700–2200]	NA	#408 [700–2200]	#896 [650–1500]	NA	NA	NA	28% [9–25]
CD3-CD16+CD56+	54% [14–30]	NA	44% [14–30]	40% [13–47]	NA	NA	NA	NA
CD3+HLA-DR+	#1600 [490–1300]	NA	#1122 [490–1300]	#1280 [370–1100]	NA	NA	NA	NA
IgG mg/dl	18% [16–35]	NA	28% [16–35]	11% [3.5–15.5]	NA	NA	NA	NA
IgM mg/dl	#532 [390–1400]	NA	#714 [390–1400]	#352 [270–860]	NA	NA	NA	NA
IgA mg/dl	16.4% [3–15]	NA	5% [3–15]	3.7% [4.5–30]	NA	NA	NA	NA
	#485 [130–720]	NA	#128 [130–720]	#118 [100–720]	NA	NA	NA	NA
	0.1%	NA	3.4%	0.5%	NA	NA	NA	1%
	21%	NA	28%	11%	NA	NA	NA	NA
	27%	NA	25.6%	33%	NA	NA	NA	NA
	546 [745–1804]	NA	235 [745–1804]	725 [764–2134]	NA	NA	NA	584 [987–1958]
	130 [78–261]	NA	99 [78–261]	45 [69–387]	NA	NA	NA	27.3 [83–282]
	24 [57–282]	NA	10 [57–282]	12 [78–383]	NA	NA	NA	26 [96–465]

EBV, Epstein-Barr virus; PLT, platelet; ANC, absolute neutrophil count; ALC, absolute lymphocyte count, HSCt; hematopoietic stem cell transplantation; ICE, ifosfamide, etoposide, carboplatin; COPP, cyclophosphamide, vincristine, procarbazine, prednisone; OEPA, vincristine, etoposide, prednisone, doxorubicin; COPP/ABV, cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine. Abnormal values are given in italics. Respective age reference values are given in brackets and # represents absolute cell counts

Table 2 Transplant-related data of the three patients who underwent hematopoietic stem cell transplant

	V1	V3	V4
Age at HSCT	5.5 years	6 years	8 years
Donor source	10/10 matched unrelated	10/10 mother	10/10 mother
Conditioning regimen	Treosulfan/fludarabin	Treosulfan/fludarabin	Treosulfan/fludarabin
GvHD prophylaxis	CsA + MMF + Post-Tx CyC	CsA + Post-Tx CyC	CsA
CD34+ stem cell dose	5.7×10^6 /kg	5×10^6 /kg	5.4×10^6 /kg
Engraftment days	Neutrophil: 12 Lymphocyte: 18 Thrombocyte: 10	Neutrophil: 13 Lymphocyte: 21 Thrombocyte: 12	Neutrophil: 11 Lymphocyte: 10 Thrombocyte: 11
Post-tx complications	None	Grade 2 chronic skin GvHD	Grade 3 acute skin and liver GvHD
Follow-up time after transplant (tr)	3 months	11 months	17 months
Last laboratory investigations after tr.	At 3rd month	At 9th month	At 15th month
T cell chimerism	100%	100%	100%
IgG	840 mg/dl	692 mg/dl	583 mg/dl
IgA	54 mg/dl	48 mg/dl	26 mg/dl
IgM	92 mg/dl	110 mg/dl	121 mg/dl
CD3%	93	59	68
CD4%	5	29	19
CD8%	80	22	46
CD19%	0.2	19	5
CD16+56%	4	11	16
Ongoing treatments	Prophylactic antimicrobials-CsA	Prophylactic antimicrobials-prednisolon (for 2 months, now tapering)*	Prophylactic antimicrobials-CsA prednisolon (for 10 months, now tapering)

*Cyclosporin A was given for 9 months as GvHD prophylaxis and was stopped. After 2 months, GvHD recurred and responded to prednisolone, cyclosporin A was not given again. 2 mg/kg/day prednisolon was started as initial dose; if there is a response after 2 weeks, the dose was tapered by 10–25% every 2 weeks according to maintenance of response

autologous stem cell transplantation. Due to severe recurrent infections and history of consanguineous marriage in the family, combined immunodeficiency was suspected and she underwent an allogeneic transplantation from the mother, who was a full match donor, 29 months after termination of treatment for HL. Fludarabine and treosulfan were used as conditioning regimen; lymphocyte engraftment was achieved at day 21 post-transplant. Full donor chimerism in both total and T cell was achieved. Cyclosporin A and post-transplant cyclophosphamide were used for graft versus host (GvHD) prophylaxis. Grade 2 chronic skin GvHD was observed at 9 months post-transplant, which responded to steroids (which is tapered) and post-transplant cyclophosphamide. Her Karnofsky/Lansky performance score is 100. She is under follow-up for 48 months since diagnosis of HL and with no evidence of disease.

On family history, another sibling (V-2) had died of infection at 40 days of age. Soon after the two siblings' (V-1 and V-3) referral to our center, a 14-year-old female relative (IV-10) was referred to our center with encephalitis due to HSV1

infection and recurrent pneumonia. The family history revealed that the siblings of the patient (IV-10) were previously diagnosed with HL (IV-7, diagnosed at age 15 and died at 20, and IV-8, diagnosed at age 12, currently in remission at age 17). Paternal aunt of this patient (who was also a maternal aunt of V-1 and V-3) has been diagnosed with endometrium cancer (III-6).

Due to the diagnosis of HL in two siblings (V-1 and V-3) born to consanguineous parents, family history of sibling and cousins with severe infections and malignancies, and recurrent infections, an association with EBV was suspected, and the level of EBV DNA levels at admission to our center was found to be significantly elevated (V-1 43,900 copies/ml; V-3 14,067 copies/ml). The EBV DNA levels were further elevated at relapse (V-1 185761; V-3 309,242 copies/ml). An inherited immunodeficiency was also suspected and both siblings were evaluated for immunodeficiency including complete blood counts; flow cytometry of peripheral blood for CD3, CD4, CD8, CD45, CD19, and CD16; HLA-DR

counts; and IgG, IgA, and IgM levels (Table 1). Both had severe CD4 T cell lymphopenia and low immunoglobulin levels and were diagnosed with combined immunodeficiency (Table 1). In both siblings, immunoglobulin replacement and prophylactic antibiotics were initiated. In both patients EBV DNA levels were negative (values below 100 copies/ml were considered normal) after allogeneic stem cell transplantation.

Index patients' parents and the 6-year-old brother (V-4) who had cervical lymphadenomegalies were also evaluated. The brother (V-4) was also found to have elevated EBV DNA levels (47,566 copies/ml) and was also diagnosed with combined immune deficiency (Table 1). There was no malignancy in the excisional biopsy of the enlarged lymph nodes. He underwent an allogeneic transplantation from the mother, who was a full match donor, 15 months after diagnosis of CID. Fludarabine-treosulfan was used as conditioning regimen. Cyclosporin A was given for graft versus host (GVHD) prophylaxis. He achieved lymphocyte engraftment on day 10 with donor chimerism of 100%, respectively. He developed grade 2 acute GVHD with skin and liver involvement in the second month of transplantation, which responded to steroids. The GvHD recurred at 11 months post-transplant and responded to steroids. He is clinically well for 12 months since allogeneic transplantation with Karnofsky/Lansky performance score of 100. His EBV DNA levels were also negative after the allogeneic SCT.

The first sibling (V1) diagnosed with CID and HL, underwent allogeneic stem cell transplantation from the matched unrelated donor 51 months after diagnosis and 37 months after the termination of treatment for relapsed HL. He did not experience a further relapse before the transplantation. Fludarabine-treosulfan was used as conditioning regimen. Cyclosporin A and post-transplant cyclophosphamide were given as graft versus host (GVHD) prophylaxis. He achieved lymphocyte engraftment on day 14 with full donor chimerism on the first month of transplantation. Now, he is at the third month after transplantation and there is no evidence of GvHD. All three siblings are clinically well with IVIG replacement and prophylactic antibiotics, V-1 for 52 months, V-3 for 48 months since diagnosis of HL, and V-4 for 27 months since diagnosis of CID. After transplantation, IVIG replacement was given to all three patients for three to four times when the IgG level was < 400 mg/dl. Transplant-related data of the three patients who underwent allogeneic hematopoietic stem cell transplantation are presented in Table 2.

All analyses were performed after the approval of Istanbul University Medical Faculty Ethical Board; written and oral informed consents were taken from the family members or legal representatives.

Exome Sequencing

Peripheral blood of the patients at remission and healthy individuals were obtained (denoted with asterisk (* or **) in pedigree in Fig. 1) and DNA was isolated with column-based method of QIAamp DNA Blood Mini kit according to the manufacturer's instructions. Quantity and purity of DNA samples were assessed with spectrophotometry.

A whole exome sequencing (WES) approach was performed by using Agilent SureSelect Human All ExonV6 kit for exome capturing. Illumina's raw data was aligned to hg19 reference genome with BWA and SAMtools to generate final BAM file and variant list. For the selection of candidate genes, whole variant list was filtered, where intronic and synonymous variant were left out. Remaining variants were prioritized according to their MAF (< 0.01, reported by 1000Genomes, ExAC, and gnomAD). For the clinical interpretation of candidate variants OMIM, ClinVar's known reports (benign/pathogenic/uncertain), PolyPhen's and SIFT's predictions, and conservation scores (CADD) were evaluated. Sanger sequencing was used to validate and familial segregation analysis was performed for the candidate variations.

Kappa Deleting Excision Circle Analysis

Kappa deleting excision circle (KREC) analysis was performed to homozygous mutation carriers (V-1, V-3, and V-4), heterozygous parents (IV-3 and IV-4), and age-matched healthy controls. All KREC analyses were performed during remission and after autologous bone marrow transplantations for V-1 and V-3. KREC copy numbers were detected by quantitative real-time PCR (qRT-PCR) assay on a LC96 real-time PCR System (Roche USA). TRAC gene was used as housekeeping gene. Primers, probes, and PCR conditions were previously described [44].

Results

Variants revealed by exome sequencing of index (V-3) were filtered in the following order: exonic and splice sites, non-synonymous, homozygous, and finally to variants with MAF < 0.01 and all identified candidate variants were given in Supplementary Table 1. Among the genes, which are known to be associated with immunodeficiency and predisposition to EBV-associated lymphoma, we have identified a homozygous missense variation in the *CD70* and a non-synonymous, heterozygous exonic variant in *ITK* with MAF < 0.01 (rs17054374), which is reported in ClinVar as having conflicting interpretation (uncertain significance and benign).


Additional homozygous variations were also identified in *COL5A3*, *UACA*, and *USP17L10* genes which are predicted as disease causing, probably damaging, and deleterious

according to 3 different prediction tools (Mutation Taster, PolyPhen and SIFT). There is no ClinVar or OMIM phenotype data for those genes. Germline *UACA* loss-of-function variations were previously reported in one study in colorectal cancer [45], *COL5A3* variants were reported as genetic risk factor for autism spectrum disorder [46], and *USP17L10* gene variation was classified as variant unknown significance (VUS). *CD70* variation is the strongest candidate among the others fulfilling the clinical presentation that was previously reported and suited recessive inheritance pattern. This missense variation (NM_001252.5:c.332C>T) was previously identified (rs1378830614) with a frequency of $7.95577e-06$ (2/251390, heterozygous in two individuals) and presented in gnomAD database. No previous association was reported about the functional impact or clinical outcome of the variation. Familial segregation analysis confirmed all siblings as homozygous and parents as heterozygous for the *CD70* mutation (Fig. 2a). Mother's (IV-4) cousin (IV-10) was also homozygous for this mutation.

In silico prediction tools predict as probably damaging (Polyphen) and deleterious (SIFT) and the position is widely conserved between the species. This nucleotide is highly conserved (CADD scores of 25.8) and its amino acid is located in the extra cytoplasmic TNF domain of CD70 protein that is the region that CD70 interacts with CD27 (Fig. 3a–c).

KREC analysis carried out in affected homozygous patients (V-1, V-3, and V-4), heterozygous parents (IV-3 and IV-4), and healthy controls. The results showed that patients with immune deficiency and EBV-associated HL (V-1 and V-3) showed much higher KREC copies (197,893 copies and 168,269 copies, respectively) compared with heterozygous parents (IV-3: 22,000 copies and IV-4: 25,900 copies) and healthy controls childhood average count 29,900 copies (max count 98,000 copies) and adult average count 5290 (max count 29,100 copies) (Fig. 2b). V-4 who did not develop HL but only had immune deficiency had KREC copy numbers (35,832 copies) comparable with parents and healthy controls.

Fig. 2 **a** Sanger validation of NM_001252.5:c.332C>T mutation. **b** KREC copy numbers in homozygous mutant, heterozygous and homozygous wild type individuals. Each patient's sample was studied in technical replicates and the results were compared with the age-matched controls both for childhood and adults



Discussion


Increased risk of cancer development in immune deficient patients has been acknowledged previously [47–52]. A study conducted on 3658 primary immunodeficiency patients in the USIDNET cohort reported a cancer incidence of 4.7%, of which 48% were diagnosed with lymphoma, 15% skin cancer, 8% genitourinary cancer, 8% gastrointestinal, 6% breast cancer, 5% endocrine cancer, 4% head and neck cancer, 3% lung cancer, 1% bone cancer, and 2% cancers with unspecified origin [51, 52].

Several primary immune deficiencies have high predisposition to malignancies, especially to EBV-associated lymphoproliferative disorders due to the impaired anti-viral response. Germline mutations in genes *SH2D1A*, *ITK*, *MAGT1*, *CORO1A*, *CD27*, *CD70*, *CTPS1*, *TNFRSF9*, *STK4*, *CARMIL2*, *PRKCD*, and *RASGRP1* are associated with a high incidence of EBV-associated lymphomas [26–29].

CD27 and CD70 are TNF family members and function as homodimer type I and homotrimer type II membrane proteins, respectively [30]. CD70-CD27 pathway is very important for immune surveillance of B cells and T cell immune function. CD27 is highly expressed in T cells and some B cells and acts as co-stimulatory molecule of T cell activation (Fig. 3b) [35, 53]. CD70 is expressed only in a small fraction of B cells. CD70's expression is highly upregulated on activated B cells and EBV-infected B cells. When CD27 on T cells or CD70 on B cells have defects and impair the CD27-CD70 axis, anti-viral response of T cells toward EBV-infected cells is impaired which in turn leads to lymphoproliferative disorder [13]. All of the previously reported mutation sites, including our report, are located in the extracellular domain of CD70, which might explain the association with immune deficiency and impaired response to EBV (Fig. 3a).

Up to date six cases with CID and/or EBV-related Hodgkin's lymphoma with *CD70* mutation have been reported. Caorsi et al. reported *CD70* mutation in a case with EBV-

Fig. 3 **a** Schematic view of CD70 protein and previously reported mutations, **b** schematic view of T cell and antigen presenting cell's (APC) interaction. **c** NM_001252.5:c332C conservation across vertebrae (base G with gray underline)



positive recurrent infections and without leukemia or lymphoma development [12]. Abolhassani et al. reported two separate families with two different *CD70* variations: in the first family, patients with *CD70* mutations had presented with viral encephalitis or immune deficiency or EBV-associated HL, and in the second family, two patients were diagnosed with immune deficiency and EBV-positive HL [11]. Izawa et al. also reported a case with immune deficiency and EBV-positive HL [13].

In the present study, four members of a family were identified with *CD70* homozygous mutations; two had combined immunodeficiency, high titers of EBV DNA, and HL (V-1)(V-3); one was diagnosed with immune dysregulation (V-4); and one who had encephalitis and recurrent infections (IV-10) is being investigated for immunodeficiency. Apart from our case (V-10), only one patient with *CD70* deficiency is reported with viral encephalitis although the causative agent is not known in the latter [11]. The patients described till now are either presented with recurrent infections including severe viral infections suggesting a combined immune deficiency or with immune dysregulation and especially malignancy. The susceptibility to EBV is remarkable, whereas varicella pneumonia and herpes simplex encephalitis were also noted [11]. Laboratory evaluations of the patients in the literature varied from normal to decreased T cells, decreased T and B cells, and/or abnormal antibody responses. So far, we do not have data suggesting dysgammaglobulinemia following EBV infections like in X-linked lymphoproliferative syndrome [11–13].

All reported *CD70* mutated patients who developed lymphoma had specifically Hodgkin lymphoma. Approximately 40% of Hodgkin lymphomas are associated with EBV infections with the predominance of mixed cellularity subtype [54]. EBV is thought to serve as an anti-apoptotic functionary to

provide the escape of BCR-negative Hodgkin-Reed-Sternberg cells from the immune surveillance [55]. The origins of Hodgkin lymphoma are not fully elucidated and the preference for the HL in the case of germline *CD70* mutations may be an interesting matter to focus. *CD70* may play a role specifically in these BCR-negative Hodgkin-Reed-Sternberg cells.

Kappa deleting excision circles are DNA segments generated in B cells during their maturation in the bone marrow. These segments are unable to replicate and consequently are diluted following cell divisions. Thus, KRECs can be used as a diagnostic tool in evaluating new lymphocyte output [56]. Until now, KREC measures were not reported in lymphoma patients. In this study, we found higher KREC levels in homozygous *CD70* deficient patients who developed lymphoma. Interestingly, the other affected patient without lymphoma diagnosis showed KREC levels similar to healthy controls and heterozygous carriers. Kappa deleting excision circles occur during T cell-independent phase of B cell development in the bone marrow and are generated during the maturation from large pre B II cells to small pre B II cells [56]. Izawa et al. suggested that *CD70* expressed on B cells might act as a signaler in the case of abnormal B cell proliferation to T cells. Additionally, somatic *CD70* mutations are found in B cell lymphomas, especially diffuse large B cells and Burkitt's lymphoma [57–59]. Thus, we may speculate that *CD70* deficiency may result in abnormal B cell development following EBV encountering and leading to development of lymphoma. The normal KREC levels in patient V-4 may support this hypothesis. On the other hand, the samples were drawn following autologous transplantation for V-1 and V-3, which may also reflect the reconstitution of B cells. Nevertheless, this finding needs further investigations and is weak due to lack of inadequate number of patient data.

Exome sequencing has an advantage in identifying disease-causing gene(s) especially in a heterogeneous disease group such as immune deficiency and cancer predisposition syndromes with long and growing list of genes. In this study, exome sequencing has enabled us to identify the *CD70* mutation in multiple family members with immunodeficiency and malignancies. We were able to identify the homozygous mutation in three siblings and the heterozygous mutation in both parents and a homozygous mutation in a distant cousin. The identification of this mutation has also implications for surveillance of other family members. Unfortunately, despite many communications, the second family consented for the analysis of only the child who had had life-threatening infection (encephalitis); they are further referred for clinical surveillance in the center in their local setting.

Although autologous stem cell transplantation is a known treatment option in recurrent Hodgkin lymphoma, in patients with immune deficiency, allogeneic stem cell transplantation is recommended. Thus, consanguineous marriages, history of recurrent infections in the family, or family history of HL should alert the physician for immune deficiency. Two of the patients in this study (V1 and V3) had undergone autologous stem cell transplantation for relapsed Hodgkin Lymphoma prior to the diagnosis of immune deficiency and *CD70* mutation.

In conclusion, primary immune deficiency patients are predisposed to malignancies, especially lymphomas [60]. *CD70* mutation has rarely been reported in CID and/or Hodgkin lymphoma. In families with consanguineous marriages, with family history of recurrent or severe infections, or family history of HL, especially if multiple members are affected, individuals should be investigated for EBV DNA levels, immune deficiency, and *CD70* mutation.

Acknowledgments This project is supported by Istanbul University Research Fund with the project number: TOA 20499 and by Bilgi University Research Fund: 2018.01.006. The authors thank Prof Emin Darendeliler, Dr. Ayca Iribas, Istanbul University, Oncology Institute, Department of Radiation Oncology; Assoc. Prof Muge Gokce, Bahcelievler Memorial Hospital and The Stem Cell Transplantation Unit of the Medicalpark, Bahcelievler Hospital for the support in the treatment of the patients; and Emine Hafize Erdeniz from Erzurum Education and Research Hospital for providing patient information.

Authors' Contributions M. Sayitoglu and R. Kebudi supervised the study. All authors contributed to the data collection. K. Khodzhaev and Y. Erbilgin directed the data analysis and family analysis. Y. Y. Ng, D. Altindirek, and O. H. Ng performed and analyzed the KREC study and provided molecular biology expertise. R. Kebudi and S. B. Bay provided clinical oncology expertise. A. Kaya and A. Kiykim provided clinical immunology expertise. F. Çipe Erol and B. Adaklı Aksoy provided allogeneic transplantation expertise, patient material, and clinical data for the study. F. Sen Zengin provided the patient material and data in Erzurum. Data analyses of molecular findings were performed by K. Khodzhaev, S.

Firtina, and Y. Erbilgin. Data interpretation was carried out by R. Kebudi, M. Sayitoglu, K. Khodzhaev, S. B. Bay, and A. Kiykim. All authors contributed to manuscript preparation. M. Sayitoglu and R. Kebudi reviewed the manuscript. All authors made the final approval of the manuscript.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

References

- Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, et al. Childhood cancer predisposition syndromes—a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. *Am J Med Genet A*. 2017;173(4):1017–37.
- Huck K, Feyen O, Niehues T, Rüschemdorf F, Hübner N, Laws HJ, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. *J Clin Invest*. 2009;119(5):1350–8.
- Linka RM, Risse SL, Bienemann K, Werner M, Linka Y, Krux F, et al. Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases. *Leukemia*. 2012;26(5):963–71.
- Cagdas D, et al. Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other. *Bone Marrow Transplant*. 2017;52(1):126–9.
- Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. *Blood*. 2011;117(1):53–62.
- Li FY, Chaigne-Delalande B, Kanelloupolou C, Davis JC, Matthews HF, Douek DC, et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. *Nature*. 2011;475(7357):471–6.
- Chaigne-Delalande B, Li FY, O'Connor GM, Lukacs MJ, Jiang P, Zheng L, et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. *Science*. 2013;341(6142):186–91.
- Patiroglu T, Haluk Akar H, Gilmour K, Unal E, Akif Ozdemir M, Bibi S, et al. A case of XMEN syndrome presented with severe auto-immune disorders mimicking autoimmune lymphoproliferative disease. *Clin Immunol*. 2015;159(1):58–62.
- Martin E, Palmic N, Sanquer S, Lenoir C, Hauck F, Mongellaz C, et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. *Nature*. 2014;510(7504):288–92.
- Alkhairy OK, Perez-Becker R, Driessen GJ, Abolhassani H, van Montfrans J, Borte S, et al. Novel mutations in TNFRSF7/CD27: clinical, immunologic, and genetic characterization of human CD27 deficiency. *J Allergy Clin Immunol*. 2015;136(3):703–12 e10.
- Abolhassani H, Edwards ESJ, Ikinogullari A, Jing H, Borte S, Buggert M, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. *J Exp Med*. 2017;214(1):91–106.
- Caorsi R, et al. CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever. *Front Immunol*. 2017;8:2015.
- Izawa K, Martin E, Soudais C, Bruneau J, Boutboul D, Rodriguez R, et al. Inherited CD70 deficiency in humans reveals a critical role

- for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. *J Exp Med*. 2017;214(1):73–89.
14. Moshous D, Martin E, Carpentier W, Lim A, Callebaut I, Canioni D, et al. Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. *J Allergy Clin Immunol*. 2013;131(6):1594–603.
 15. Punwani D, Pelz B, Yu J, Arva NC, Schafermak K, Kondratowicz K, et al. Coronin-1A: immune deficiency in humans and mice. *J Clin Immunol*. 2015;35(2):100–7.
 16. Salzer E, Cagdas D, Hons M, Mace EM, Garncarz W, Petronczki ÖY, et al. RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. *Nat Immunol*. 2016;17(12):1352–60.
 17. Platt CD, Fried AJ, Hoyos-Bachiloglu R, Usmani GN, Schmidt B, Whangbo J, et al. Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. *Clin Immunol*. 2017;183:142–4.
 18. Alosaimi MF, Hoenig M, Jaber F, Platt CD, Jones J, Wallace J, et al. Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency. *J Allergy Clin Immunol*. 2019;144(2):574–83 e5.
 19. Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schäffer AA, et al. The phenotype of human STK4 deficiency. *Blood*. 2012;119(15):3450–7.
 20. Sherkat R, Sabri MR, Dehghan B, Bigdelian H, Reisi N, Afsharmoghadam N, et al. EBV lymphoproliferative-associated disease and primary cardiac T-cell lymphoma in a STK4 deficient patient: a case report. *Medicine (Baltimore)*. 2017;96(48):e8852.
 21. Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). *Blood*. 2017;130(12):1430–40.
 22. Wang Y, Ma CS, Ling Y, Bousfiha A, Camcioglu Y, Jacquot S, et al. Dual T cell- and B cell-intrinsic deficiency in humans with biallelic RLTPR mutations. *J Exp Med*. 2016;213(11):2413–35.
 23. Uchida Y, Yoshimitsu M, Kamada Y, Arima N, Ishitsuka K. A novel recurrent gain-of-function mutation of Rltpr Q575E in adult T cell leukemia/lymphoma. 2019;134(Supplement_1):1489 Ash Publications.
 24. Kuehn HS, Niemela JE, Rangel-Santos A, Zhang M, Pittaluga S, Stoddard JL, et al. Loss-of-function of the protein kinase C delta (PKCdelta) causes a B-cell lymphoproliferative syndrome in humans. *Blood*. 2013;121(16):3117–25.
 25. Salzer E, Santos-Valente E, Klaver S, Ban SA, Emminger W, Prengemann NK, et al. B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C delta. *Blood*. 2013;121(16):3112–6.
 26. Bousfiha A, Jeddane L, Picard C, al-Herz W, Ailal F, Chatila T, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. *J Clin Immunol*. 2020;40(1):66–81.
 27. Latour S, Winter S. Inherited immunodeficiencies with high predisposition to Epstein-Barr virus-driven lymphoproliferative diseases. *Front Immunol*. 2018;9:1103.
 28. Tangye SG. Genetic susceptibility to EBV infection: insights from inborn errors of immunity. *Hum Genet*. 2020;139(6–7):885–901.
 29. Tangye SG, Latour S. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection. *Blood*. 2020;135(9):644–55.
 30. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R, et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. *Cell*. 1993;73(3):447–56.
 31. Bowman MR, et al. The cloning of CD70 and its identification as the ligand for CD27. *J Immunol*. 1994;152(4):1756–61.
 32. Goodwin RG, Din WS, Davis-Smith T, Anderson DM, Gimpel SD, Sato TA, et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. *Eur J Immunol*. 1993;23(10):2631–41.
 33. Brown GR, et al. CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes. *J Immunol*. 1995;154(8):3686–95.
 34. Hintzen RQ, et al. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. *J Immunol*. 1995;154(6):2612–23.
 35. Hendriks J, Gravestien LA, Tesselaar K, van Lier RAW, Schumacher TNM, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. *Nat Immunol*. 2000;1(5):433–40.
 36. Arens R, Tesselaar K, Baars PA, van Schijndel GMW, Hendriks J, Pals ST, et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFN γ -mediated B cell depletion. *Immunity*. 2001;15(5):801–12.
 37. van Montfrans JM, Hoepelman AIM, Otto S, van Gijn M, van de Corput L, de Weger RA, et al. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. *J Allergy Clin Immunol*. 2012;129(3):787–93 e6.
 38. Nolte MA, van Oeffen RW, van Gisbergen KPJM, van Lier RAW. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. *Immunol Rev*. 2009;229(1):216–31.
 39. Croft M. The role of TNF superfamily members in T-cell function and diseases. *Nat Rev Immunol*. 2009;9(4):271–85.
 40. Lens SM, et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. *Br J Haematol*. 1999;106(2):491–503.
 41. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. *Blood*. 1995;85(12):3556–65.
 42. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. *Clin Cancer Res*. 2008;14(23):7763–72.
 43. Rejin Kebudi SBB, Gorgun O, Agaoglu FY, Zulfikar B, Ayan I, Iribas A, et al. Risk adapted treatment in childhood Hodgkin's lymphoma: outcome and changing epidemiologic features in 25 years. *Blood*. 2016;128(22).
 44. Firtina S, Ng YY, Ng OH, Nepesov S, Yesilbas O, Kilercik M, et al. A novel pathogenic frameshift variant of CD3E gene in two T-B+ NK+ SCID patients from Turkey. *Immunogenetics*. 2017;69(10):653–9.
 45. Gylfe AE, Katainen R, Kondelin J, Tanskanen T, Cajuso T, Hänninen U, et al. Eleven candidate susceptibility genes for common familial colorectal cancer. *PLoS Genet*. 2013;9(10):e1003876.
 46. Krupp DR, Barnard RA, Duffourd Y, Evans SA, Mulqueen RM, Bernier R, et al. Exonic mosaic mutations contribute risk for autism spectrum disorder. *Am J Hum Genet*. 2017;101(3):369–90.
 47. Mortaz E, et al. Cancers related to immunodeficiencies: update and perspectives. *Front Immunol*. 2016;7:365.
 48. Gangemi S, Allegra A, Musolino C. Lymphoproliferative disease and cancer among patients with common variable immunodeficiency. *Leuk Res*. 2015;39(4):389–96.
 49. Jonkman-Berk BM, van den Berg JM, ten Berge IJM, Bredius RGM, Driessen GJ, Dalm VASH, et al. Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy. *Clin Immunol*. 2015;156(2):154–62.
 50. Filipovich AH, et al. Primary immunodeficiencies: genetic risk factors for lymphoma. *Cancer Res*. 1992;52(19 Suppl):5465s–7s.
 51. Mayor PC, Eng KH, Singel KL, Abrams SI, Odunsi K, Moysich KB, et al. Cancer in primary immunodeficiency diseases: cancer

- incidence in the United States Immune Deficiency Network Registry. *J Allergy Clin Immunol*. 2018;141(3):1028–35.
52. Kebudi R, Kiykim A, Sahin MK. Primary immunodeficiency and cancer in children; a review of the literature. *Curr Pediatr Rev*. 2019;15(4):245–50.
 53. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. *Curr Opin Immunol*. 2005;17(3):275–81.
 54. Massini G, Siemer D, Hohaus S. EBV in Hodgkin lymphoma. *Mediterr J Hematol Infect Dis*. 2009;1(2):e2009013.
 55. Vockerodt M, Cader FZ, Shannon-Lowe C, Murray P. Epstein-Barr virus and the origin of Hodgkin lymphoma. *Chin J Cancer*. 2014;33(12):591–7.
 56. Serana F, Chiarini M, Zanotti C, Sottini A, Bertoli D, Bosio A, et al. Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies. *J Transl Med*. 2013;11:119.
 57. Bertrand P, Maingonnat C, Penther D, Guney S, Ruminy P, Picquenot JM, et al. The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma. *Genes Chromosom Cancer*. 2013;52(8):764–74.
 58. Giefing M, Arnemann J, Martin-Subero JI, Niëländer I, Bug S, Hartmann S, et al. Identification of candidate tumour suppressor gene loci for Hodgkin and Reed-Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines. *Br J Haematol*. 2008;142(6):916–24.
 59. Scholtysik R, Nagel I, Kreuz M, Vater I, Giefing M, Schwaenen C, et al. Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas. *Int J Cancer*. 2012;131(5):E830–5.
 60. Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. *Cancer Epidemiol Biomark Prev*. 2007;16(3):405–8.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.